Befovacimab
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI) . Befovacimab can be used for haemophilia A/B research[1].
Product Specifications
CAS Number
2156634-62-5
Product Name Alternative
BAY 1093884
UNSPSC
12352203
Target
Thrombin; Tissue Factor Pathway Inhibitor (TFPI)
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton; Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/befovacimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Befovacimab]
Molecular Weight
(142.98 kDa)
References & Citations
[1]Maria Elisa Mancuso, et al. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis. Haemophilia. 2022 Sep;28 (5) :702-712. |[2]Jian-Ming Gu, et al. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. AAPS J. 2017 Jul;19 (4) :1186-1195.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
